Introduction
Invasive fungal infections are on the increase and are a challenge to the clinician. Until recently, there have been very few systemic antifungal agents available. amphotericin B was considered standard treatment, but its well-known side effects have made physicians reluctant to use it. Recently, triazoles have been developed, among them fluconazole, which is available for both oral and intravenous administration and is much better tolerated than amphotericin. This forms the rationale of this trial comparing fluconazole with amphotericin B for the empiric treatment of febrile neutropenics, with suspected invasive fungal infections.
Methods
• A prospective, randomized unblinded study 
Results
There were equal number of successors (68% vs 67%) and failures (8% vs 6%) in both arms; however, neither reached statistical significance. The incidence of drug withdrawal due to toxicity was higher in the amphotericin group (7% vs 1%; P = 0.005). Interestingly 13% of the patients treated with the fluconazole needed to have treatment changed to amphotericin B for lack of clinical improvement, as opposed to 2% treated with amphotericin b (P < 0.001).
Additional information
Candida species are the prominent fungal pathogens, followed by Aspergillus species and occasionally other opportunistic fungi in febrile neutropenics. In patients without neutropenia, fluconazole has been shown to be as effective as amphotericin B in the treatment of Candidemia.
